1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Business Builds: Life Sciences Capital Program is sponsored by Massachusetts Life Sciences Center (MLSC). Supports companies creating or expanding their presence in biomanufacturing or medtech advanced manufacturing in Massachusetts. This program funds capital investments, such as buildout, renovation, or equipment needs, and aims to support increased activity and career development in Massachusetts.
Projects demonstrating broader public benefit, workforce training space, access for small local companies, or collaboration with nonprofit partners are prioritized.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Companies engaged in life sciences research, development, commercialization, and manufacturing in Massachusetts, particularly those creating or expanding their presence in biomanufacturing or medtech advanced manufacturing. Confirm the full requirements in the official notice before applying.
The current listing shows $500,000 to $2,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Business Builds: Life Sciences Capital Program are due June 30, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Business Builds: Life Sciences Capital Program is funded by Massachusetts Life Sciences Center (MLSC). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Massachusetts. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleAwards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read article